SARS-CoV-2 replication triggers an MDA-5-dependent interferon production which is unable to efficiently control replication
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third highly pathogenic coronavirus to spill over to humans in less than 20 years, after SARS-CoV-1 in 2002-2003 and Middle East respiratory syndrome (MERS)-CoV in 2012. SARS-CoV-2 is the etiologic agent of coronavirus disease 19 (COVID-19), which ranges from mild respiratory symptoms to severe lung injury and death in the most severe cases. The COVID-19 pandemic is currently a major health issue worldwide. Immune dysregulation characterized by altered innate cytokine responses is thought to contribute to the pathology of COVID-19 patients, which is a testimony of the fundamental role of the innate immune response against SARS-CoV-2. Here, we further characterized the host cell antiviral response against SARS-CoV-2 by using primary human airway epithelia and immortalized model cell lines. We mainly focused on the type I and III interferon (IFN) responses, which lead to the establishment of an antiviral state through the expression of IFN-stimulated genes (ISGs). Our results demonstrate that both primary airway epithelial cells and model cell lines elicit a robust immune response characterized by a strong induction of type I and III IFN through the detection of viral pathogen molecular patterns (PAMPs) by melanoma differentiation associated gene (MDA)-5. However, despite the high levels of type I and III IFNs produced in response to SARS-CoV-2 infection, the IFN response was unable to control viral replication, whereas IFN pre-treatment strongly inhibited viral replication and de novo production of infectious virions. Taken together, these results highlight the complex and ambiguous interplay between viral replication and the timing of IFN responses.
Article activity feed
-
SciScore for 10.1101/2020.10.28.358945: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources An overnight incubation at 4°C with mab J2 (Scicons) followed by incubation in a secondary anti-mouse antibody conjugated to Alexa Fluor 546 and in Alexa Fluor 488 Phalloidin (Thermofisher Scientific) for 2h at RT were used to visualise dsRNA and F-actin, respectively. F-actinsuggested: NoneCells were incubated on ice for 30-45 min in FACS buffer (PBS1X-5% FCS) containing a 1/250 dilution of Alexa 488-conjugated anti-Spike antibody (GTX632604 conjugated … SciScore for 10.1101/2020.10.28.358945: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources An overnight incubation at 4°C with mab J2 (Scicons) followed by incubation in a secondary anti-mouse antibody conjugated to Alexa Fluor 546 and in Alexa Fluor 488 Phalloidin (Thermofisher Scientific) for 2h at RT were used to visualise dsRNA and F-actin, respectively. F-actinsuggested: NoneCells were incubated on ice for 30-45 min in FACS buffer (PBS1X-5% FCS) containing a 1/250 dilution of Alexa 488-conjugated anti-Spike antibody (GTX632604 conjugated using the Zenon Alexa Fluor 488 Mouse IgG Labeling Kit, ThermoFisher) and washed 4 times in FACS buffer. anti-Spikesuggested: (GeneTex Cat# GTX632604, RRID:AB_2864418), RIG-I (Covalab mab10110), MDA-5 (Ozyme D74E4), and MAVS (ProteinTech 14341-1-AP), followed by secondary horseradish peroxidase-conjugated anti-mouse or anti-rabbit immunoglobulin antibodies and chemiluminescence Clarity or Clarity max substrate (Bio-Rad). RIG-Isuggested: NoneMDA-5suggested: (Cell Signaling Technology Cat# 5321, RRID:AB_10694490)anti-mousesuggested: Noneanti-rabbit immunoglobulinsuggested: NoneExperimental Models: Cell Lines Sentences Resources Caco-2 and Calu-3 cells were obtained from American Type Culture Collection (ATCC); HEK-Blue™ IFN-α/β and IFN-γ cells were obtained from InvivoGen; 293T, MDCK, A549, Vero E6 cells were gifts from Michael Malim’s lab, Wendy Barclay’s lab, and from the CEMIPAI facility, respectively. Caco-2suggested: NoneMDCKsuggested: NoneVero E6suggested: RRID:CVCL_XD71)A549 and Caco-2 cells stably expressing ACE2 and TMPRSS2 were generated by transduction with either RRL.sin.cPPT.SFFV/IRES-puro.WPRE, RRL.sin.cPPT.SFFV/IRES-neo.WPRE, RRL.sin.cPPT.SFFV/IRES-hygro.WPRE or RRL.sin.cPPT.SFFV. A549suggested: NCI-DTP Cat# A549, RRID:CVCL_0023)Cas9 activity was checked using the XPR_047 assay (a gift from David Root, Addgene 107145) and was 79.5% and >83.4%, respectively, for Cas9-expressing A549-ACE2 and Calu-3 cells. Calu-3suggested: KCLB Cat# 30055, RRID:CVCL_0609)Lentiviral production and infection: Lentiviral vector stocks were obtained by polyethylenimine (PEI; for LentiGuides) or Lipofectamine 3000 (Thermo Scientific; for ACE2 and TMPRSS2 lentiviral vectors)-mediated multiple transfection of 293T cells in 6-well plates with vectors expressing Gag-Pol, the miniviral genome, the Env glycoprotein at a ratio of 1:1:0.5. 293Tsuggested: None, RIG-I (Covalab mab10110), MDA-5 (Ozyme D74E4), and MAVS (ProteinTech 14341-1-AP), followed by secondary horseradish peroxidase-conjugated anti-mouse or anti-rabbit immunoglobulin antibodies and chemiluminescence Clarity or Clarity max substrate (Bio-Rad). MDA-5suggested: NoneSoftware and Algorithms Sentences Resources Post-processing of RAW Airyscan images was performed using the Zen Black software. Zen Blacksuggested: (Black Zen software, RRID:SCR_018163)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
